Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Generate Biomedicines
Axogen Corporation
Celgene
WinSanTor, Inc
Axogen Corporation
Conjupro Biotherapeutics, Inc.
Eisai Inc.
Celgene
Celgene
Celgene
Egetis Therapeutics
Swiss Medical Food AG
iOMEDICO AG
Oncotherapeutics
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NEMA Research, Inc.
NeoTherapeutics